Curis to report Q1 2026 financial results and host webcast on May 12

Curis, a biotech company developing the drug emavusertib for cancer treatment, will announce its first quarter 2026 financial and operating results on May 12, 2026. The company will hold a conference call and webcast to discuss these results. Emavusertib is being tested in clinical trials for lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia, with orphan drug designations from the FDA and European Commission. This update is important for investors tracking Curis's progress in cancer drug development and financial health.